Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 45 results.
User Information
Export Records
  1. 1.   IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
  2. Bolomsky, Arnold; Ceribelli, Michele; Scheich, Sebastian; Rinaldi, Kristina; Huang, Da Wei; Chakraborty, Papiya; Pham, Lisette; Wright, George W; Hsiao, Tony; Morris, Vivian; Choi, Jaewoo; Phelan, James D; Holewinski,Ronald; Andresson,Thorkell; Wisniewski, Jan; Riley, Deanna; Pittaluga, Stefania; Hill, Elizabeth; Thomas, Craig J; Muppidi, Jagan; Young, Ryan M
  3. Cancer Cell. 2024, Jul 8; 42(7): 1185-1201.
  1. 2.   Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 Booster Vaccination
  2. Rosati, Margherita; Terpos, Evangelos; Bear,Jenifer; Burns,Robert; Devasundaram,Santhi; Ntanasis-Stathopoulos, Ioannis; Gavriatopoulou, Maria; Kastritis, Efstathios; Dimopoulos, Meletios-Athanasios; Pavlakis, George N; Felber,Barbara
  3. Cancers. 2022, Nov 25; 14(23):
  1. 3.   Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
  2. Salama, April K S; Li, Shuli; Macrae, Erin R; Park, Jong-In; Mitchell, Edith P; Zwiebel, James A; Chen, Helen X; Gray, Robert J; McShane, Lisa M; Rubinstein, Larry V; Patton, David; Williams,Mickey; Hamilton, Stanley R; Armstrong, Deborah K; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
  3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020, NOV 20; 38(33): JCO2000762.
  1. 4.   CD19-positive antibody-secreting cells provide immune memory
  2. Groves, C. J.; Carrell, Jeff; Grady, R.; Rajan, B.; Morehouse, C. A.; Halpin, R.; Wang, J.; Wu, J.; Shrestha, Y.; Rayanki, R.; Kolbeck, R.; Wang, Y.; Herbst, R.
  3. Blood advances. 2018, NOV 27; 2(22): 3163-3176.
  1. 5.   Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies
  2. Nayar, Utthara; Sadek, Jouliana; Reichel, Jonathan; Hernandez-Hopkins, Denise; Akar, Gunkut; Barelli, Peter J.; Sahai, Michelle A.; Zhou, Hufeng; Totonchy, Jennifer; Jayabalan, David; Niesvizky, Ruben; Guasparri, Ilaria; Hassane, Duane; Liu, Yifang; Sei, Shizuko; Shoemaker, Robert; Warren, J. David; Elemento, Olivier; Kaye, Kenneth M.; Cesarman, Ethel
  3. JOURNAL OF CLINICAL INVESTIGATION. 2017, Jun; 127(6): 2066-2080.
  1. 6.   Antitumor Activity of a Novel Oncrasin Analogue Is Mediated by JNK Activation and STAT3 Inhibition
  2. Guo, W.; Wu, S. H.; Wang, L.; Wei, X. L.; Liu, X. Y.; Wang, J.; Lu, Z. M.; Hollingshead, M.; Fang, B. L.
  3. Plos One. 2011, Dec; 6(12):
  1. 7.   Variation in innate immunity genes and risk of multiple myeloma
  2. Purdue, M. P.; Lan, Q.; Menashe, I.; Zheng, T. Z.; Zhang, Y. W.; Yeager, M.; Hosgood, H. D.; Zahm, S. H.; Chanock, S. J.; Rothman, N.; Baris, D.
  3. Hematological Oncology. 2011, Mar; 29(1): 42-46.
  1. 8.   Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors
  2. Lee, S.; Yagita, H.; Sayers, T. J.; Celis, E.
  3. Cancer Immunology Immunotherapy. 2010, Jul; 59(7): 1073-1081.
  1. 9.   JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo
  2. Kiziltepe, T.; Anderson, K. C.; Kutok, J. L.; Jia, L.; Boucher, K. M.; Saavedra, J. E.; Keefer, L. K.; Shami, P. J.
  3. Journal of Pharmacy and Pharmacology. 2010, Jan; 62(1): 145-151.
  1. 10.   Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo
  2. Hanse, E. A.; Nelsen, C. J.; Goggin, M. M.; Anttila, C. K.; Mullany, L. K.; Berthet, C.; Kaldis, P.; Crary, G. S.; Kuriyama, R.; Albrecht, J. H.
  3. Cell Cycle. 2009 8(17): 2802-2809.
  1. 11.   The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
  2. Lucas, D. M.; Edwards, R. B.; Lozanski, G.; West, D. A.; Shin, J. D.; Vargo, M. A.; Davis, M. E.; Rozewski, D. M.; Johnson, A. J.; Su, B. N.; Goettl, V. M.; Heerema, N. A.; Lin, T. S.; Lehman, A.; Zhang, X. L.; Jarjoura, D.; Newman, D. J.; Byrd, J. C.
  3. Blood. 2009 113(19): 4656-4666.
  1. 12.   Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
  2. Sissung, T. M.; Thordardottir, S.; Gardner, E. R.; Figg, W. D.
  3. Anti-cancer agents in medicinal chemistry. 2009 9(10): 1058-1069.
  1. 13.   Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition
  2. Hallett, W.; Ames, E.; Motarjemi, M.; Barao, I.; Shanker, A.; Tamang, D. L.; Sayers, T. J.; Hudig, D.; Murphy, W. J.
  3. Journal of Immunology. 2008 180(1): 163-170.
  1. 14.   Caspase polymorphisms and genetic susceptibility to multiple myeloma
  2. Hosgood, H. D.; Baris, D.; Zhang, Y.; Zhu, Y.; Zheng, T.; Yeager, M.; Welch, R.; Zahm, S.; Chanock, S.; Rothman, N.; Lan, Q.
  3. Hematological Oncology. 2008 26(3): 148-151.
  1. 15.   Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
  2. Shanker, A.; Brooks, A. D.; Tristan, C. A.; Wine, J. W.; Elliott, P. J.; Yagita, H.; Takeda, K.; Smyth, M. J.; Murphy, W. J.; Sayers, T. J.
  3. Journal of the National Cancer Institute. 2008 100(9): 649-662.
  1. 16.   One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia
  2. Lee, K. M.; Lan, Q.; Kricker, A.; Purdue, M. P.; Grulich, A. E.; Vajdic, C. M.; Turner, J.; Whitby, D.; Kang, D.; Chanock, S.; Rothman, N.; Armstrong, B. K.
  3. Human Genetics. 2007, Dec; 122(5): 525-533.
  1. 17.   Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines
  2. Hurt, E. M.; Thomas, S. B.; Peng, B.; Farrar, W. L.
  3. British Journal of Cancer. 2007, Oct; 97(8): 1116-1123.
  1. 18.   Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo
  2. Gills, J.; Lo Piccolo, J.; Tsurutani, J.; Shoemaker, R. H.; Best, C. J. M.; Abu-Asab, M. S.; Borojerdi, J.; Warfel, N. A.; Gardner, E. R.; Danish, M.; Hollander, M. C.; Kawabata, S.; Tsokos, M.; Figga, W. D.; Steeg, P. S.; Dennis, P. A.
  3. Clinical Cancer Research. 2007, Sep; 13(17): 5183-5194.
  1. 19.   Thalidomide analogues as anticancer drugs
  2. Aragon-Ching, J. B.; Li, H. Q.; Gardner, E. R.; Figg, W. D.
  3. Recent Patents on Anti-Cancer Drug Discovery. 2007, Jun; 2(2): 167-174.
  1. 20.   Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator
  2. Hurt, E. M.; Thomas, S. B.; Peng, B.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2006, Sep; 5(9): 1154-1160.
  1. 21.   Importance of the stress kinase p38 alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells
  2. Warfel, N. A.; Lepper, E. R.; Zhang, C. Y.; Figg, W. D.; Dennis, P. A.
  3. Clinical Cancer Research. 2006, Jun; 12(11): 3502-3509.
  1. 22.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 23.   Inhibition of transcription factor NF-kappa B signaling proteins IKK beta and p65 through specific cysteine residues by epoxyquinone A monomer: Correlation with its anti-cancer cell growth activity
  2. Liang, M. C.; Bardhan, S.; Pace, E. A.; Rosman, D.; Beutler, J. A.; Porco, J. A.; Gilmore, T. D.
  3. Biochemical Pharmacology. 2006, FEB 28; 71(5): 634-645.
  1. 24.   JS-K, a GST-activated nitric oxide generator, induces apoptosis and overcomes in vitro drug resistance in multiple myeloma cells
  2. Kiziltepe, T.; Ishitsuka, K.; Hideshima, T.; Raje, N.; Shiraishi, N.; Yasui, H.; Catley, L.; Chauhan, D.; Saavedra, J. E.; Keefer, L. K.; Shami, P. J.; Anderson, K. C.
  3. Blood. 2005, NOV 16; 106(11, Part 1): 456A, Abstract 1593-456A, Abstract 1593.
  1. 25.   The role of IL-6 and STAT3 in inflammation and cancer
  2. Hodge, D. R.; Hurt, E. M.; Farrar, W. L.
  3. European Journal of Cancer. 2005, NOV; 41(16): 2502-2512.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel